This is a **Sample** version of the **QUALITY OF LIFE IN LATE-STAGE DEMENTIA (QUALID) SCALE**

The **full version** of QUALITY OF LIFE IN LATE-STAGE DEMENTIA (QUALID) SCALE comes without ‘sample’ watermark.

The full complete (9 page)version includes –

- Clinical Study & results
- Review
- Administration Instructions
- Complete 11 sets of question criteria

**Buy full version here - Buy now for $7.00**

Once you have paid for your item you will receive a direct link to download your full complete e-book instantly. You will also receive an email with a link to download your e-book. Each purchased product you order is available to download for 24 hours from time of purchase.
QUALITY OF LIFE IN LATE-STAGE DEMENTIA (QUALID) SCALE

A Clinical Study - Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease.

Hadas Benhabib¹, Krista L. Lancot, PhD ¹,²,⁴, Goran M. Eryavec, MD, FRCPc ³,⁴, Abby Li, Msc¹, and Nathan Henmann, MD, FRCPc ¹,⁴

¹Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, ON; ²Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON; ³North York General Hospital, Toronto, ON; ⁴Department of Psychiatry, University of Toronto, Toronto, ON

ABSTRACT

Background

This study aimed to determine whether the Quality of Life in Late-Stage Dementia (QUALID) scale is responsive to changes in behaviour due to therapeutic intervention.

Method

31 long-term care residents with moderate to severe AD and agitation/aggression entered a three-month, open-label trial of memantine 10 mg BID. The relationships between the QUALID and BPSD, global improvement, and cognition at baseline and endpoint, as well as the changes in these scales as a result of treatment, were examined.

Results

Despite a significant improvement in agitation and aggression (NPI agitation, F 3.90 = 3.721, p = .014; CMAI total, F 3.90 = 6.301, p = .001) and overall behaviour (NPI total, F 3.90 = 4.035, p = .010), there was no significant change in QUMID score (S 2.97 = .278, p = .783). The QUALID was correlated with NPI at baseline (r = 0.270, p = .037) and endpoint (r = 0.404, p = .002), but change scores were not correlated (r = 0.107, p = .412).

Conclusion

While the QUALID correlates with behavioural measures at single time points, it does not appear to correlate with changes longitudinally associated with treatment.

Key words: QUALID, quality of life, dementia

INTRODUCTION

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and functional impairment and behavioural and psychological symptoms of dementia (BPSD).¹ These neuropsychiatric symptoms commonly include delusions, hallucinations, agitation, disinhibition, apathy, irritability, anxiety, depression, sleep disturbances, and elation.²BPSD are highly common in severe dementia, with 90% of individuals exhibiting at least one behaviour. Up to 50% of patients exhibit at least four behaviours during the course of the illness.³It has previously been shown that even modest improvements in these behaviours can result in significant improvement in the quality of life (QoL) for the patient.²

Although there is still a lack of agreement about how QoL should be defined and measured, it is generally considered to be a multidimensional construct that includes the individual’s subjective experience of life, as well as objective criteria related to activities valued by society.⁴Engagement in positive activities, presence of positive affect, absence of negative affect, participation in meaningful activity, and a sense of community are assumed to be correlated with QoL in late-stage dementia.⁵⁻⁷There is a growing consensus about the need to measure QoL in dementia trials, as such assessments allow researchers to evaluate the benefits and harms of a treatment and elements of health not detected by standard clinical outcomes.⁸⁻¹⁰However, it is very difficult to determine QoL in persons with late-stage dementia as they cannot communicate reliably and are not involved in activities widely accepted by others as rewarding.¹¹Due the severity of cognitive impairment of patients with moderate to severe AD, assessment must rely on proxy reports or direct observation. (u) Unfortunately, both of these approaches tend to exclude consideration of the patient’s subjective experiences, which many believe to be an inherent feature of QoL.⁸⁻¹²
The Quality of Life in Late-stage Dementia (QUALID) scale was originally developed by Weiner and co-workers in 2000(10) The QUALID is a late-stage, dementia-specific questionnaire with a one-week window of observation. It provides information about the patient's quality of life through assessments made by proxy informants. The scale consists of 11 items, comprising both positive and negative dimensions of concrete and observable mood and performance, thought to be indicative of QoL in late-stage dementia. The items are rated by frequency of occurrence on a five-step scale, and scores are summed to range from 11 (best QoL) to 55 (worst QoL). While the QUALID scale has been shown to obtain reliable estimates of QoL in moderate to severe dementia residing in long-term care facilities,(13,15) little is known about the scale's responsiveness to change due to therapeutic intervention.

The objective of this study was to assess the responsiveness of the QUALID scale to changes in BPSD due to a therapeutic intervention in a population of long-term care residents with moderate to severe AD. As well, this study evaluated the relationship between the QUALID scale and the severity of BPSD as determined by standard validated research scales.

**DISCUSSION**

It has been suggested that treatments designed to alleviate BPSD may have beneficial effects for patients' QoL, as a strong relationship between BPSD and QoL has been previously observed. The significant relationship between the NPI and CMAI with the QUALID scores at baseline and final assessment suggest that QoL is associated with behavioural symptoms in moderate to severe AD. This result supports conclusions drawn by previous studies examining the relationship between the QUALID scale and BPSD at a single point in time; however, changes in the QUALID score from baseline to endpoint did not correlate with change scores on the NPI, CMAI or CGI. This lack of relationship suggests that the QUALID scale may not be responsive to changes in BPSD. Concurrent validity was tested, by comparing QUALID change scores in patients who improved based on the NPI and patients who did not. As the mean change in QUALID scores was similar between both groups, this once again suggests that the QUALID may not be responsive to changes in BPSD.

A previous study looking at the responsiveness of the QUALID scale to drug treatment found that the QUALID was responsive to the changes in BPSD.(23) The discrepancy in this finding may be due to the difference in study length (i.e., 14 days in the previous study compared to three months in the current). It is possible that any short-term benefits from decreased behavioural problems are washed out by deterioration in overall health status over the long term. Differences in results may also reflect differences in the study population. The population in the previous study included 31 late-stage dementia patients residing in long-term care facilities who were given either olanzapine or risperidone. The patients had a mean baseline QUALID of 30.94 and mean NPI of 53.48, both of which are higher than those of the current study and other papers that have studied the QUALID scale (10,13,14). This study design reflects a more realistic timeframe for a therapeutic intervention, and is comparable to many other studies using antipsychotics (23) with a drug that has shown to improve behavioural symptoms in moderate to severe AD(15). The population is similar to most other studies in terms of mean QUALID and MMSE scores, even though the NPI scores were slightly higher than those previously shown. Therefore, this analysis presents an appropriate design for a study involving patients with moderate to severe Alzheimer's disease residing in long-term care facilities, and, as a result, should provide more applicable conclusions regarding the responsiveness of the QUALID scale to change when a therapeutic intervention is implemented.

**Limitations**

The major limitation of the study was the open-label design. It is also unclear whether family caregiver assessment of QoL would differ from nurses' assessments. It is possible that re-sults attained from the QUALID scale are accurate, and that to make an impact in patients' QoL over the long term, larger changes in behaviour, cognition, and function are necessary. Another possibility is that the effects of memantine were not strong enough to elicit a change in QoL in the long-term, despite significant improvements in behaviour rating scales.

Another limitation is the fact that the majority of the patients in this study were male, and therefore the results may not necessarily be applicable to the general population of institutionalized patients with dementia. However, gender does not appear to have a significant effect on quality of life in those with dementia. While one study did find that being female was a significant predictor of lower quality of life as measured by the QUALID, there was no difference between males and females in actual QUALID scores, and the authors did not consider the results robust. (29)

**CONCLUSION**

QoL assessments provide another format for individuals and their caregivers to express whether an intervention made an important difference in the patient's life. As important clinical decisions may be drawn from perceived QoL effects, it is vital that the QoL data be reliable, valid, and responsive to change. Although the QUALID scale demonstrated that QoL is associated with BPSD in moderate to severe AD, it was unable to reflect change when a therapeutic intervention for BPSD was implemented. These results suggest that methods of assessing QoL in moderate to severe AD that are responsive to change are still needed, especially if they are to play an important role in assessing treatment benefits.

This is the end of the sample QUALID Clinical study. To purchase full complete version please go to page 1 (top page).
The QUALID is administered in interview format to an informant following the instructions below.

Informants may be either a family member or professional caregiver who by having regular contact is familiar with the subject’s general behavior. Informants must, in addition to being familiar with the subject, have spent a significant portion of at least 3 days out of the last 7 days with the subject, in order to accurately rate the items on the scale. The scale is scored by summing the responses. The possible scores range from 11 to 55, with 11 representing the highest quality of life.

The final items on the scale require that the interviewer make a judgement about the validity of the interview. Provide both a rating of the overall quality of the interview, which includes the informant’s ability to understand the items and responses and the effort the informant put forth in answering questions, and the familiarity of the informant with the subject. These items are not included in the score, but offer information about the validity and usefulness of the ratings for that subject.

Informants are handed a blank copy of the scale so that they may look at the items as they are read aloud, and the following instructions are given:

I want to ask you some questions about name’s quality of life. I want you to rate his/her behaviors using the responses under each question on this page. (point to the responses on the first question) There is no one right or wrong answer, I just want to know how you would rate his/her behavior from your observations.

Specifically, I want to know about his/her behavior over the past week only, not how he/she previously behaved. Remember that your answers should reflect his/her behavior over the past seven days. If you are not sure what the question means, you can ask me about it. If you have difficulty choosing a rating for an item, just make your best guess. Again, indicate your observation about his/her behavior over the past week.

Which response best describes ________ over the past week?

A. [S] smiles
   1. spontaneously once or more each day
   2. spontaneously less than once each day
   3. only in response to external stimuli; at least once each day
   4. only in response to external stimuli; less than once each day
   5. rarely, if at all

B. [S] appears sad
   1. rarely or never
   2. only in response to external stimuli; less than once each day
   3. only in response to external stimuli; at least once each day
   4. for no apparent reason less than once each day
   5. for no apparent reason once or more each day

C. [S] cries
   1. rarely or never
   2. only in response to external stimuli; less than once each day
   3. only in response to external stimuli; at least once each day
   4. for no apparent reason less than once each day
   5. for no apparent reason once each day or more

This is the end of the sample QUALID questionnaire. To purchase the complete 11 sets of question criteria please go to page 1 (top page).